ascopubs.org

A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.

Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Secondary analysis of the SPARTAN trial. This is an ASCO Meeting Abstract ...
ascopubs.org

First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors.

Using artificial intelligence-powered evidence-based molecular decision-making for improved outcomes in ovarian cancer. A phase II study of anlotinib plus albumin-bound paclitaxel in patients with ...